Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Apr 5;3(3):e648.
doi: 10.1097/PR9.0000000000000648. eCollection 2018 May.

Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report

Affiliations
Case Reports

Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report

Launette Marie Rieb et al. Pain Rep. .

Abstract

Introduction and objectives: Understanding the details of one individual's experience with pain, opioid use and withdrawal may generate insights into possible relationships between opioid-induced hyperalgesia and withdrawal-associated injury site pain (WISP).

Methods: This case study was extracted from a mixed methods study that characterized WISP. In 2014, the individual was recruited from a primary care clinic that prescribes opioid agonist therapy. In an interview, she completed a 35-item survey and elaborated on her own experience. Follow-up contact was made in June of 2017.

Results: This 34-year-old white woman had several twisting injuries of her right knee between ages 13 and 15. The pain resolved each time in a few days, and she was pain free for 15 years. Around age 30, she initiated illicit oxycodone recreationally (not for pain) and developed an opioid use disorder. On detoxification, she experienced severe knee pain for 6 weeks that resolved postdetoxification but returned after subsequent oxycodone use and withdrawal episodes along with generalized skin sensitivity. This experience of WISP became a barrier to opioid cessation. Although nonsteroidal anti-inflammatories and gabapentin relieved WISP and methadone therapy assisted her opioid use disorder, an eventual change to sublingual buprenorphine/naloxone provided superior control of both.

Conclusion: This case report illustrates that both opioid use and withdrawal can reactivate injury site pain, which can increase with dose escalation and repeated withdrawal events. The timing, trajectory, and neuropathic features of WISP reported here are consistent with those previously reported for the development of opioid-induced hyperalgesia, possibly linking these phenomena.

Keywords: Drug dependence; Hyperalgesia; Opioids; Pain; Withdrawal syndrome.

PubMed Disclaimer

Conflict of interest statement

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Similar articles

Cited by

References

    1. Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 2015;29:465–86. - PubMed
    1. Ballantyne JC. Opioid therapy in chronic pain. Phys Med Rehabil Clin N Am 2015;26:201–18. - PubMed
    1. Bannister K. Opioid-induced hyperalgesia: where are we now? Curr 2015;9:116–21. - PubMed
    1. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clinic Proc 2015;90:828–42. - PubMed
    1. Bie B, Fields HL, Williams JT, Pan ZZ. Roles of alpha1- and alpha2-adrenoceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia. J Neurosci 2003;23:7950–7. - PMC - PubMed

Publication types

LinkOut - more resources